This is a randomized 36-month, Phase III, safety study to assess the long-term safety of Viaskin® Peanut, dosed at 250 µg peanut protein (per patch) in peanut-allergic children from 4 through 11 years of age.
The study design is in 2 main parts:
* A randomized, double-blind, placebo-controlled design for the first 6 months of treatment,
* Followed by an open-label, single arm active treatment design with Viaskin® Peanut 250 µg for remaining 30 months.
